CDTX
Price
$18.93
Change
-$2.61 (-12.12%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
207.24M
CPRX
Price
$23.92
Change
-$0.33 (-1.36%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
2.95B
35 days until earnings call
Ad is loading...

CDTX vs CPRX

Header iconCDTX vs CPRX Comparison
Open Charts CDTX vs CPRXBanner chart's image
Cidara Therapeutics
Price$18.93
Change-$2.61 (-12.12%)
Volume$1.74K
Capitalization207.24M
Catalyst Pharmaceuticals
Price$23.92
Change-$0.33 (-1.36%)
Volume$27.49K
Capitalization2.95B
CDTX vs CPRX Comparison Chart
Loading...
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDTX vs. CPRX commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDTX is a StrongBuy and CPRX is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (CDTX: $21.54 vs. CPRX: $24.25)
Brand notoriety: CDTX and CPRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDTX: 74% vs. CPRX: 104%
Market capitalization -- CDTX: $207.24M vs. CPRX: $2.95B
CDTX [@Biotechnology] is valued at $207.24M. CPRX’s [@Biotechnology] market capitalization is $2.95B. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDTX’s FA Score shows that 0 FA rating(s) are green whileCPRX’s FA Score has 2 green FA rating(s).

  • CDTX’s FA Score: 0 green, 5 red.
  • CPRX’s FA Score: 2 green, 3 red.
According to our system of comparison, CPRX is a better buy in the long-term than CDTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDTX’s TA Score shows that 2 TA indicator(s) are bullish while CPRX’s TA Score has 5 bullish TA indicator(s).

  • CDTX’s TA Score: 2 bullish, 5 bearish.
  • CPRX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CPRX is a better buy in the short-term than CDTX.

Price Growth

CDTX (@Biotechnology) experienced а -8.84% price change this week, while CPRX (@Biotechnology) price change was -5.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.07%. For the same industry, the average monthly price growth was -13.26%, and the average quarterly price growth was -12.25%.

Reported Earning Dates

CDTX is expected to report earnings on Aug 13, 2024.

CPRX is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-9.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CPRX($2.95B) has a higher market cap than CDTX($207M). CPRX YTD gains are higher at: 16.195 vs. CDTX (-19.866). CPRX has higher annual earnings (EBITDA): 233M vs. CDTX (-175.87M). CPRX has more cash in the bank: 518M vs. CDTX (190M). CPRX has less debt than CDTX: CPRX (3.19M) vs CDTX (3.58M). CPRX has higher revenues than CDTX: CPRX (492M) vs CDTX (1.28M).
CDTXCPRXCDTX / CPRX
Capitalization207M2.95B7%
EBITDA-175.87M233M-75%
Gain YTD-19.86616.195-123%
P/E RatioN/A18.26-
Revenue1.28M492M0%
Total Cash190M518M37%
Total Debt3.58M3.19M112%
FUNDAMENTALS RATINGS
CDTX vs CPRX: Fundamental Ratings
CDTX
CPRX
OUTLOOK RATING
1..100
8420
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
67
Overvalued
PROFIT vs RISK RATING
1..100
10013
SMR RATING
1..100
10033
PRICE GROWTH RATING
1..100
3938
P/E GROWTH RATING
1..100
10077
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDTX's Valuation (52) in the Biotechnology industry is in the same range as CPRX (67) in the Pharmaceuticals Other industry. This means that CDTX’s stock grew similarly to CPRX’s over the last 12 months.

CPRX's Profit vs Risk Rating (13) in the Pharmaceuticals Other industry is significantly better than the same rating for CDTX (100) in the Biotechnology industry. This means that CPRX’s stock grew significantly faster than CDTX’s over the last 12 months.

CPRX's SMR Rating (33) in the Pharmaceuticals Other industry is significantly better than the same rating for CDTX (100) in the Biotechnology industry. This means that CPRX’s stock grew significantly faster than CDTX’s over the last 12 months.

CPRX's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as CDTX (39) in the Biotechnology industry. This means that CPRX’s stock grew similarly to CDTX’s over the last 12 months.

CPRX's P/E Growth Rating (77) in the Pharmaceuticals Other industry is in the same range as CDTX (100) in the Biotechnology industry. This means that CPRX’s stock grew similarly to CDTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDTXCPRX
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
71%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 5 days ago
87%
Bullish Trend 9 days ago
80%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 2 days ago
68%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
67%
View a ticker or compare two or three
Ad is loading...
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEVRX22.090.16
+0.73%
First Eagle US R6
FTDWX13.57N/A
N/A
Fidelity Advisor Asset Manager 20% M
IRCIX12.36N/A
N/A
Voya Russell Small Cap Index Port S2
TLATX10.49N/A
N/A
Transamerica Large Core ESG I3
BINKX9.39N/A
N/A
BlackRock Infrastructure Sust Opps K

CDTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDTX has been closely correlated with BPTSY. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if CDTX jumps, then BPTSY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDTX
1D Price
Change %
CDTX100%
-3.80%
BPTSY - CDTX
92%
Closely correlated
N/A
IVVD - CDTX
36%
Loosely correlated
+0.88%
CPRX - CDTX
35%
Loosely correlated
-1.78%
CABA - CDTX
33%
Poorly correlated
-10.65%
TRAW - CDTX
30%
Poorly correlated
-4.17%
More

CPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CPRX has been loosely correlated with SANA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CPRX jumps, then SANA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPRX
1D Price
Change %
CPRX100%
-1.78%
SANA - CPRX
45%
Loosely correlated
-1.75%
VIR - CPRX
39%
Loosely correlated
-3.28%
CRNX - CPRX
36%
Loosely correlated
-3.43%
ATXS - CPRX
35%
Loosely correlated
-6.32%
CMPX - CPRX
35%
Loosely correlated
-4.52%
More